The discovery of cis-platin and its second and third generation analogues created a hope in cancer chemotherapy. Cis-platin and its second generation analogue carboplatin have been used for the treatment of some cancers from a long time. The third generation analogues have superior anti-cancer profiles for curing a few cancers. Unfortunately, certain side effects such as renal impairment, neurotoxicity and ototoxicity etc. are associated with these drugs. But, combination therapy makes these analogues more effective with fewer side effects. In addition, the results of some ongoing clinical trials will make the safety profile clear in near future. The present article describes the current status of cis-platin and its analogues in cancer chemotherapy. In addition, special emphasis has been made on cis-platin discovery, development of second (carboplatin, oxaliplatin, nedaplatin) and third (lobaplatin, heptalatin) generation analogues, comparison of their chemotherapies, mechanism of action, therapeutic status, recent developments and chronology. Moreover, attempts have been made to describe the future perspectives of these drugs in the cancer treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.